MedTrace Logo

Phase I/II Study of Genasense in Patients With Chronic Lymphocytic Leukemia

NCT00021749 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2009-11-13

No results posted yet for this study

Summary

This non-randomized study will test the safety and effectiveness of Genasense in patients with CLL.

Conditions

Interventions

DRUG

Oblimerson sodium, G3139

Sponsors & Collaborators

  • Genta Incorporated

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-01-31
Primary Completion
2003-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00021749 on ClinicalTrials.gov